Acute pancreatitis, not really. Obviously I haven't seen that particular patient detailed data to make informed decision, but the company's decision to move to higher dose tells me they are not worried about it. PGNX is generally conservative, look at the trial data, they enrolled 6 more patients in 1.8 dose cohort (total 9 instead of 3) to make sure dose wasn't the issue so they can move to 2 dose level.
Market Data 
Markets 
AI
